CBST on NASDAQ

Cubist Pharmaceuticals

Logo: Grmike, Public domain, via Wikimedia Commons4

Defunct American pharmaceutical company

Cubist Pharmaceuticals, Inc. was an American biopharmaceutical company that targeted pathogens like MRSA. .3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 18, 2026.

Overview

1992Founded1

Compare with another stock.

  • TickerCBST on NASDAQ1
  • IndustryPharmaceutical Preparations1
  • HeadquartersLexington1
  • Websitewww.cubist.com
  • Incorporated inDE5
  • Business address65 Hayden Avenue, Lexington, Ma 024215
  • Filer categoryLarge accelerated filer5

See how the biggest companies compare on our leaderboards

Cubist Pharmaceuticals, Inc. was an American biopharmaceutical company that targeted pathogens like MRSA.3

The story

Cubist was founded in May 1992 by John K. Clarke, Paul R. Schimmel, Ph.D. and Barry M. Bloom, Ph.D, all of whom were also directors.

Cubist appeared on Fortune 2010’s List of fastest growing companies, and was named to the 2010 Deloitte Technology Fast 500.

In 2011, the company acquired Adolor, maker of a drug for treatment of constipation.

In July 2013, Cubist Pharmaceuticals agreed to purchase Trius Therapeutics and Optimer Pharmaceuticals for around $1.6 billion.

In 2014, succeeding Michael Bonney as President, Robert J. Perez, was announced to take leadership on January 1, 2015.

In January 2015, Cubist Pharmaceuticals became a wholly owned subsidiary of Merck & Co.

From Wikipedia’s article on Cubist Pharmaceuticals, shared under CC BY-SA 4.0.6

Leadership

Who has led Cubist Pharmaceuticals, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Michael W. Bonney2006–2015
  2. Robert J. Perez2015

President

  1. Michael W. Bonney2006–2013
  2. Robert J. Perez2012–2014

Chief financial officer

  1. David W. J. McGirr2006–2013
  2. Michael John Tomsicek2013–2015

Chief operating officer

  1. Robert J. Perez2009–2014
  2. Patrick V.j.j. Vink2015
1995200020052010201520202025
Board members and other officers (28)

Products and brands

The company developed Cubicin (daptomycin) for injection, the first antibiotic in a class of anti-infectives called lipopeptides. In 2011, Cubist settled a patent litigation with Teva Pharmaceutical Industries regarding Cubicin.

In April 2011 it reached a deal with Optimer Pharmaceuticals in which its class of bacterium-fighting drugs will be co marketed with Optimer's Fidaxomicin/Dificid (for $15 million per year).

In 2011, its product pipeline focused on gram-negative bacterial infections, Clostridioides difficile infection, and respiratory syncytial virus.

Tedizolid was approved by the US Food and Drug Administration on June 20, 2014.

From Wikipedia’s article on Cubist Pharmaceuticals, shared under CC BY-SA 4.0.6

Timeline

  1. Jan 5, 2015New chief executive Robert J. Perez becomes CEO7
  2. 2015Dissolved Dissolved1
  3. Jan 5, 2006New chief executive Michael W. Bonney becomes CEO8
  4. 1992Founded Founded1

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40